bluebird bio Secures $75 Million in Private Placement Equity Financing

08 Sep, 2021

bluebird bio Secures $75 Million in Private Placement Equity Financing
Photo by Pawel Chu on Unsplash

– bluebird bio, Inc. announced that it has entered into an agreement for a $75m private placement of common stock and common stock equivalents with a healthcare investment fund selected as part of a competitive process.
– Proceeds from the financing will support ongoing R&D and commercialization investments for bluebird bio and for 2seventy bio, which plan to launch as independent companies in October 2021.
– bluebird plans to complete the spin-off of 2seventy in October 2021, subject to customary conditions, including effectiveness of the Form 10, a favorable opinion from the IRS with respect to the tax-free nature of the transaction, and final approval from bluebird’s Board of Directors.

Biotechnology Genetics Health Diagnostics North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: